Filing Details
- Accession Number:
- 0001179110-20-012070
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-17 18:58:55
- Reporting Period:
- 2020-12-15
- Accepted Time:
- 2020-12-17 18:58:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1650664 | Editas Medicine Inc. | EDIT | Biological Products, (No Disgnostic Substances) (2836) | 464097528 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1682323 | Charles Albright | C/O Editas Medicine, Inc. 11 Hurley St. Cambridge MA 02141 | Evp/Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-12-15 | 10,000 | $16.51 | 34,907 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-12-15 | 5,776 | $62.74 | 29,131 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-15 | 4,024 | $63.84 | 25,107 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-12-15 | 200 | $64.39 | 24,907 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-12-15 | 10,000 | $0.00 | 10,000 | $16.51 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 145,000 | 2026-09-08 | No | 4 | M | Direct |
Footnotes
- The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.
- This transaction was executed in multiple trades at prices ranging from $62.18 to $63.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $63.24 to $64.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020.
Billionaire Hedge Funds
